At the news
? BULLISHIMPACT 6/10 8-K filed Nov 2, 2026 at 08:06 ET
NRx Pharmaceuticals announced FDA approval of its ANDA for Preservative-Free Ketamine, ahead of the November 10, 2026 GDUFA goal date. The product is a preservative-free formulation of ketamine manufactured in the U.S. with Nephron Pharmaceuticals, addressing a drug shortage. The company has commercial supply on hand and can now label and supply hospitals and clinics.
- FDA approved NRx's ANDA for Preservative-Free Ketamine on October 30, 2026, ahead of the November 10, 2026 GDUFA goal date.
- The product contains no benzethonium chloride (BZT), a preservative not designated as GRAS by the FDA.
- Ketamine injection has been in short supply since 2018 and is on the FDA drug shortage list.
- NRx has manufactured commercial supply on hand and can now label and supply American hospitals and clinics.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access